A carregar...
6-thioguanine selectively kills BRCA2 defective tumours and overcomes PARP inhibitor resistance
Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors are tested for these tumours in clinical trials. In a screen for novel drugs that selectively...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2010
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2913123/ https://ncbi.nlm.nih.gov/pubmed/20631063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3416 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|